Literature DB >> 17458701

Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review.

Umberto Goglia1, Diego Ferone, Marilena Sidoti, Renato Spaziante, Patrizia Dadati, Jean-Luis Ravetti, Giuseppe Villa, Lisa Bodei, Giovanni Paganelli, Francesco Minuto, Massimo Giusti.   

Abstract

Herein we report a rare case of a pituitary metastasis from a neuroendocrine tumour mimicking an adenoma. Moreover, starting from this unusual case, the relevant literature concerning the diagnosis and management of patients with metastasis at pituitary level is reviewed. A 69-year-old woman was admitted to our Unit for severe headache, diplopia, and critical visual field impairment. MRI showed a large pituitary mass compressing the optic chiasm and infiltrating the cavernous sinus. Trans-sphenoidal biopsy revealed a pituitary metastasis from a neuroendocrine tumour, in line with the multiple liver lesions that were already considered metastases from an ileal primary neuroendocrine tumour. In vitro receptor characterisation of both pituitary and liver tissues by immunohistochemistry showed a heterogeneous somatostatin receptor subtype pattern, with a predominant expression of sst(2) within the pituitary lesion. However, the liver metastasis receptor profile was completely different from the pituitary. Octreotide LAR was administered first, followed by receptor radiometabolic therapy with radiolabelled somatostatin analogues ((90)Y-DOTATOC and (177)Lu-DOTATATE). After 16 months, MRI showed a significant shrinkage of the sellar mass. Moreover, disappearance of diplopia and visual defects, together with a considerable improvement in quality of life were gradually recorded. To our knowledge, this is the first case of combined treatment using "cold" and radiolabelled octreotide in a pituitary metastasis from a neuroendocrine tumour.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17458701     DOI: 10.1007/s11102-007-0038-6

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  31 in total

Review 1.  Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara Grana; Paola Rocca; Mirco Bartolomei; Marco Chinol; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-19       Impact factor: 9.236

2.  [Pituitary metastasis from small-cell bronchial carcinoma with hyperprolactinemia].

Authors:  C Gernez-Lestradet; S Buchet; J Ranfaing; E Mollet
Journal:  Presse Med       Date:  1991-02-09       Impact factor: 1.228

3.  Metastatic carcinoma to the pituitary gland.

Authors:  P C McCormick; K D Post; A D Kandji; A P Hays
Journal:  Br J Neurosurg       Date:  1989       Impact factor: 1.596

4.  Widespread neuroendocrine malignancy within the central nervous system: a diagnostic conundrum.

Authors:  D J Hopster; S F Robinson; L Chadwick; J F Geddes
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

5.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

Authors:  Christian Waldherr; Miklos Pless; Helmut R Maecke; Tilmann Schumacher; Armin Crazzolara; Egbert U Nitzsche; Andreas Haldemann; Jan Mueller-Brand
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

6.  Malignant bronchial carcinoid tumor metastatic to the pituitary in a thyroid carcinoma patient: successful treatment with surgery, radiotherapy and somatostatin analog.

Authors:  Ilan Shimon; Moshe Hadani; Dvora Nass; S Tzila Zwas
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

7.  Pituitary apoplexy following metastasis of bronchogenic adenocarcinoma to a prolactinoma.

Authors:  F W Hanna; O M Williams; J S Davies; T Dawson; J Neal; M F Scanlon
Journal:  Clin Endocrinol (Oxf)       Date:  1999-09       Impact factor: 3.478

Review 8.  Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

Authors:  Marion De Jong; Roelf Valkema; Francois Jamar; Larry K Kvols; Dik J Kwekkeboom; Wout A P Breeman; Willem H Bakker; Chuck Smith; Stanislas Pauwels; Eric P Krenning
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

Review 9.  The diagnosis and medical management of advanced neuroendocrine tumors.

Authors:  Gregory A Kaltsas; G Michael Besser; Ashley B Grossman
Journal:  Endocr Rev       Date:  2004-06       Impact factor: 19.871

10.  Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy.

Authors:  Jochen Mundschenk; Nicole Unger; Stefan Schulz; Volker Höllt; Solveig Schulz; Rainer Steinke; Hendrik Lehnert
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

View more
  15 in total

Review 1.  Metastatic involvement of the pituitary gland: a systematic review with pooled individual patient data analysis.

Authors:  Wenzhuan He; Fangxiang Chen; Brian Dalm; Patricia A Kirby; Jeremy D W Greenlee
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

Review 2.  Clinical and biochemical characteristic features of metastatic cancer to the sella turcica: an analytical review.

Authors:  Ribal Al-Aridi; Katia El Sibai; Pingfu Fu; Mehreen Khan; Warren R Selman; Baha M Arafah
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

3.  14th EUNOS Congress: PORTO, PORTUGAL, 16-19 JUNE 2019.

Authors: 
Journal:  Neuroophthalmology       Date:  2019-06-07

4.  Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma.

Authors:  Jan Komor; Jean Claude Reubi; Emanuel R Christ
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

5.  First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment.

Authors:  S Baldari; F Ferraù; C Alafaci; A Herberg; F Granata; V Militano; F M Salpietro; F Trimarchi; S Cannavò
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

Review 6.  Bronchial carcinoid tumors metastatic to the sella turcica and review of the literature.

Authors:  Olga Moshkin; Fabio Rotondo; Bernd W Scheithauer; Mark Soares; Claire Coire; Harley S Smyth; Miklos Goth; Eva Horvath; Kalman Kovacs
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 7.  Pituitary metastasis from medullary carcinoma of thyroid: case report and review of literature.

Authors:  Harjinder S Bhatoe; Sonia Badwal; Vibha Dutta; N Kannan
Journal:  J Neurooncol       Date:  2008-04-12       Impact factor: 4.130

8.  Pituitary metastasis: a rare condition.

Authors:  Aida Javanbakht; Massimo D'Apuzzo; Behnam Badie; Behrouz Salehian
Journal:  Endocr Connect       Date:  2018-08-23       Impact factor: 3.335

9.  Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience.

Authors:  G Giuffrida; F Ferraù; R Laudicella; O R Cotta; E Messina; F Granata; F F Angileri; A Vento; A Alibrandi; S Baldari; S Cannavò
Journal:  Endocr Connect       Date:  2019-05-01       Impact factor: 3.335

10.  Peptide receptor targeting in cancer: the somatostatin paradigm.

Authors:  Federica Barbieri; Adriana Bajetto; Alessandra Pattarozzi; Monica Gatti; Roberto Würth; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Tullio Florio
Journal:  Int J Pept       Date:  2013-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.